Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05063591 · ADVERSE EVENTS

Adverse events

Removing Transfusion Dependence as a Barrier to Hospice Enrollment · Source last updated 2026-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
From the date of study enrollment until the date of death.
Other-event reporting threshold
0%

Information about adverse effects associated with blood transfusions were collected, only for participants in Arm A (Intervention Arm). Adverse events in the "Caregiver" arm were not collected.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Intervention Arm

Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment. Transfusion support: Patients will be offered symptom-driven transfusion support in addition to standard hospice care

0 / 100 / 1010 / 10

Group identifiers: EG000: Intervention Arm

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      Information about adverse effects associated with blood transfusions were collected, only for participants in Arm A (Intervention Arm). Adverse events in the "Caregiver" arm were not collected.
      event Groups
      1. deaths Num Affected
        10
        deaths Num At Risk
        10
        description
        Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment. Transfusion support: Patients will be offered symptom-driven transfusion support in addition to standard hospice care
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        10
        serious Num Affected
        0
        serious Num At Risk
        10
        title
        Intervention Arm
      frequency Threshold
      0
      time Frame
      From the date of study enrollment until the date of death.

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice